About the Company
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALBO News
Albireo Pharma gets grant for treatment of diseases with specific benzothiazepine and benzothiadiazepine derivatives
Discover Albireo Pharma Inc's groundbreaking patent for treating cardiovascular, metabolic, gastrointestinal, and liver diseases with innovative compounds. Learn how formula (I) derivatives offer a ...
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
and the Albireo Pharma Inc’s Bylvay (Odevixibat) label is indicated for PFIC patients ≥3 months old. HC Wainwright notes the FDA’s worries regarding the potential inability of children ...
INZY Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
Habib J Dable's Net Worth
Who is Habib J Dable? Habib J Dable has an estimated net worth of $15.2 Million. This is based on reported shares across multiple companies, which include Millendo Therapeutics, Inc., PepGen Inc ...
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
Plc Astrazeneca's Net Worth
Plc Astrazeneca has an estimated net worth of $812 Million. This is based on reported shares across multiple companies, which include Viela Bio, Inc., Aevi Genomic Medicine, Inc., PhaseBio ...
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Oncology Pharma Inc ONPH
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
MEI Pharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
aTyr Pharma, Inc. (LIFE)
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected ...
Loading the latest forecasts...